Company type | Privately held company |
---|---|
Industry | |
Founded | January 2015 | in San Francisco, California, United States
Founders |
|
Headquarters | US |
Area served | Worldwide |
Website | excision |
Excision BioTherapeutics is a biopharmaceutical company based in San Francisco focused on developing gene therapies against HIV infection.
The company has a single, CRISPR–Cas9 based therapy, EBT-101, under invesigation. Initial investigation into the therapy was conducted by the lab of Kamel Khalili, a professor at Temple University.[1][2][3][4] In July, 2023 the US Food and Drug Administration granted EBT-101 fast-track status.[5]